Jonathan Gloth, MD, explains how MK-8748's dual Tie2 agonist/VEGF inhibitor mechanism differs from VEGF blockade alone, and ...
Dante Pieramici, MD, of California Retina Consultants, framed the sustained-delivery tyrosine kinase inhibitor (TKI) EYP-1901 ...
Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.
Kodiak Sciences enrols first patient in global phase 3 ALTO clinical trial of KSI-501 in patients with diabetic macular edema: Palo Alto, California Wednesday, August 12, 2026, 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results